Abstract
Tuberculosis (TB) remains to be a global major public-health threat, causing millions of deaths each year. A major difficulty in dealing with TB is that the causative bacterium, Mycobacterium tuberculosis, can persist in host tissue for a long period of time even after treatment. Mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Latest genomic technology has enabled a high-throughput approach for identifying potential TB drug targets. Each gene product can be screened for its uniqueness to the TB metabolism, host-pathogen discrimination, essentiality for survival, and potential for chemical binding, among other properties. However, the exhaustive search for useful drug targets over the entire genome would not be productive as expected in practice. On the other hand, the problem can be formulated as pattern recognition or inductive learning and tackled with rule-based or statistically based learning algorithms. Here we review the perspective that combines machine learning and genomics for drug discovery in tuberculosis.
Keywords: Tuberculosis, persistence, machine learning, microarray, drug target.
Current Pharmaceutical Design
Title:Machine Learning and Tubercular Drug Target Recognition
Volume: 20 Issue: 27
Author(s): Li M. Fu
Affiliation:
Keywords: Tuberculosis, persistence, machine learning, microarray, drug target.
Abstract: Tuberculosis (TB) remains to be a global major public-health threat, causing millions of deaths each year. A major difficulty in dealing with TB is that the causative bacterium, Mycobacterium tuberculosis, can persist in host tissue for a long period of time even after treatment. Mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Latest genomic technology has enabled a high-throughput approach for identifying potential TB drug targets. Each gene product can be screened for its uniqueness to the TB metabolism, host-pathogen discrimination, essentiality for survival, and potential for chemical binding, among other properties. However, the exhaustive search for useful drug targets over the entire genome would not be productive as expected in practice. On the other hand, the problem can be formulated as pattern recognition or inductive learning and tackled with rule-based or statistically based learning algorithms. Here we review the perspective that combines machine learning and genomics for drug discovery in tuberculosis.
Export Options
About this article
Cite this article as:
Fu M. Li, Machine Learning and Tubercular Drug Target Recognition, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164023
DOI https://dx.doi.org/10.2174/1381612819666131118164023 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Monobactams: A Unique Natural Scaffold of Four-Membered Ring Skeleton, Recent Development to Clinically Overcome Infections by Multidrug- Resistant Microbes
Letters in Drug Design & Discovery Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Current Medicinal Chemistry Polyfunctional Antibiotics Affecting Bacterial Membrane Dynamics
Anti-Infective Agents in Medicinal Chemistry Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Current Approaches for New TB Drugs
Current Respiratory Medicine Reviews Molecular Modeling Investigation of Some New 2-mercaptoimidazoles
Current Computer-Aided Drug Design Advances and New Perspectives in Medicinal Chemistry Engineering and Bioinformatics (from IWBBIO 2015)
Current Topics in Medicinal Chemistry Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Constructive Personalized Medicine: The Potential Integration of Synthetic Biology and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery A Review of Antimycobacterial Drugs in Development
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Platensimycin: A Promising Antimicrobial Targeting Fatty Acid Synthesis
Current Medicinal Chemistry Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Deciphering the Antimicrobial Activity of Phenanthroline Chelators
Current Medicinal Chemistry The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism